According to the Zhitong Finance App, Mengke Pharmaceutical (688373.SH) released its 2023 annual performance report, achieving total revenue of 97.7764 million yuan, an increase of 88.31% over the previous year. Net loss attributable to owners of the parent company was $418 million. Net loss attributable to owners of the parent company after deducting non-recurring profit and loss of $451 million.
The main reason for the decline in profit during the reporting period was that during the reporting period, in order to enhance its core competitiveness, the company further enriched its new drug development pipeline, continued to advance R&D projects, several innovative drugs were in a critical clinical trial stage, R&D expenditure further increased, and the company's overall R&D investment remained at a high level.